Nanobiotix S.A Market Cap ($1.39 Billion)
Market Cap & Net Worth: Nanobiotix S.A (NANO)
Nanobiotix S.A market cap. Nanobiotix S.A (PA:NANO) has a market capitalization of $1.39 Billion (€1.19 Billion) as of November 1, 2026. Listed on the PA stock exchange, this France-based company holds position #7254 globally and #124 in its home market, demonstrating a 8.49% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanobiotix S.A's stock price €28.12 by its total outstanding shares 48387950 (48.39 Million). Also see how efficiently does Nanobiotix S.A generate cash for how efficiently the company converts equity into cash flow.
Nanobiotix S.A Market Cap History (2015–2026)
Nanobiotix S.A market cap history from 2015 to 2026. Data shows growth from $897.21 Million to $1.59 Billion (5.01% CAGR). Check current stock price of Nanobiotix S.A for real-time trading data and today's change.
Nanobiotix S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanobiotix S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Nanobiotix S.A growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
-14.74x
Nanobiotix S.A's market cap is -14.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $897.21 Million | $4.02 Million | -$17.00 Million | 223.45x | N/A |
| 2016 | $873.45 Million | $5.42 Million | -$21.88 Million | 161.11x | N/A |
| 2017 | $838.94 Million | $3.72 Million | -$26.14 Million | 225.40x | N/A |
| 2018 | $658.48 Million | $3.48 Million | -$30.34 Million | 189.27x | N/A |
| 2019 | $468.40 Million | $68.00K | -$50.91 Million | 6888.30x | N/A |
| 2020 | $780.67 Million | $50.00K | -$33.59 Million | 15613.49x | N/A |
| 2021 | $413.53 Million | $10.00K | -$47.00 Million | 41353.11x | N/A |
| 2022 | $204.79 Million | $4.78 Million | -$57.04 Million | 42.88x | N/A |
| 2023 | $375.63 Million | $30.06 Million | -$39.70 Million | 12.50x | N/A |
| 2024 | $171.07 Million | $-11.61 Million | -$68.13 Million | -14.74x | N/A |
Competitor Companies of NANO by Market Capitalization
Companies near Nanobiotix S.A in the global market cap rankings as of November 1, 2026. Also see Nanobiotix S.A assets under control for a full breakdown of the balance sheet.
Key companies related to Nanobiotix S.A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Nanobiotix S.A (2015–2026)
Market capitalization of Nanobiotix S.A from 2015 to today. Between 2015 and today, Nanobiotix S.A's market cap moved from $897.21 Million to $ 1.59 Billion, with a yearly change of 5.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.59 Billion | +44.21% |
| 2025 | €1.10 Billion | +544.84% |
| 2024 | €171.07 Million | -54.46% |
| 2023 | €375.63 Million | +83.43% |
| 2022 | €204.79 Million | -50.48% |
| 2021 | €413.53 Million | -47.03% |
| 2020 | €780.67 Million | +66.67% |
| 2019 | €468.40 Million | -28.87% |
| 2018 | €658.48 Million | -21.51% |
| 2017 | €838.94 Million | -3.95% |
| 2016 | €873.45 Million | -2.65% |
| 2015 | €897.21 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Nanobiotix S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.39 Billion USD |
| MoneyControl | $1.39 Billion USD |
| MarketWatch | $1.39 Billion USD |
| marketcap.company | $1.39 Billion USD |
| Reuters | $1.39 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanobiotix S.A
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more